CEA

(redirected from Cost-effectiveness analysis)
Also found in: Dictionary, Thesaurus, Medical, Financial, Wikipedia.

CEA

(Consumer Electronics Association) See CTA and consumer electronics.
Copyright © 1981-2019 by The Computer Language Company Inc. All Rights reserved. THIS DEFINITION IS FOR PERSONAL USE ONLY. All other reproduction is strictly prohibited without permission from the publisher.
References in periodicals archive ?
All the medicine costs, follow-up costs, mammogram costs and other cost items are taken from Turkish Cost-Effectiveness Analysis of Screening in Breast Cancer (10).
In cost-effectiveness analysis, we consider the value of our purchase and determine if the value and usage is going to be worth what we paid.
Cost-effectiveness needs to be supplemented not supplanted: "where economic evidence is down-valued or even deprioritised over other socially acceptable considerations...risks throwing the baby out with the bathwater." (8) The world needs more, not less, cost-effectiveness analysis (8)--so long as it respects each country's values and circumstances.
Table 4 shows the results of the cost-effectiveness analysis. Assuming a sustained weight loss of 4.2 lb and an improvement in HDL by 1.75 mg/dl, life expectancy increases by .030 years and quality-adjusted life expectancy increases by .028 QALYs across the entire intervention cohort.
The cost-effectiveness analysis, with effectiveness defined as the proportion not reaching the primary outcome, significantly favored betamethasone as well (88.4% vs.
From Theory to Practical Use Scenario 1: Cost-effectiveness Analysis The state of Pernambuco in Brazil would like to know which of two parenting programs should receive funding.
(1) The cost-effectiveness analysis can be applied as a guide to rank priority setting and make a rational decision when introducing drugs or new health technologies.
Cost-effectiveness analysis is an analytic strategy designed to generate knowledge on the attributable costs and effectiveness of two or more comparable healthcare interventions and is an important component of a comprehensive comparative effectiveness assessment (Frick & Stone, 2009; Garber, 2011; Jacobson, 2007).
Expanding HIV preexposure prophylaxis to cover people who inject drugs would reduce their disease burden by averting an estimated 26,700 new HIV infections every year, and would also benefit the health of the entire population, according to a cost-effectiveness analysis.
It is possible to note in Brazil, even as a start, utilization of the cost-effectiveness analysis carried out by the Ministry of Health conducted by the Department of Science and Technology (Departamento de Ciencia e Tecnologia [DECIT]).
This cost-effectiveness analysis doesn't take into account the added value of genetic testing in terms of family counseling.
This cost-effectiveness analysis is needed to inform resource allocation decisions, since the cost of using direct-acting antivirals to treat all those infected in the United States alone would exceed $300 billion.